Recent advances in the understanding and treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we r...

Descripción completa

Detalles Bibliográficos
Autores principales: Watts, Justin, Nimer, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081972/
https://www.ncbi.nlm.nih.gov/pubmed/30135719
http://dx.doi.org/10.12688/f1000research.14116.1
_version_ 1783345740412616704
author Watts, Justin
Nimer, Stephen
author_facet Watts, Justin
Nimer, Stephen
author_sort Watts, Justin
collection PubMed
description Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.
format Online
Article
Text
id pubmed-6081972
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-60819722018-08-21 Recent advances in the understanding and treatment of acute myeloid leukemia Watts, Justin Nimer, Stephen F1000Res Review Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals. F1000 Research Limited 2018-08-06 /pmc/articles/PMC6081972/ /pubmed/30135719 http://dx.doi.org/10.12688/f1000research.14116.1 Text en Copyright: © 2018 Watts J and Nimer S http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Watts, Justin
Nimer, Stephen
Recent advances in the understanding and treatment of acute myeloid leukemia
title Recent advances in the understanding and treatment of acute myeloid leukemia
title_full Recent advances in the understanding and treatment of acute myeloid leukemia
title_fullStr Recent advances in the understanding and treatment of acute myeloid leukemia
title_full_unstemmed Recent advances in the understanding and treatment of acute myeloid leukemia
title_short Recent advances in the understanding and treatment of acute myeloid leukemia
title_sort recent advances in the understanding and treatment of acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081972/
https://www.ncbi.nlm.nih.gov/pubmed/30135719
http://dx.doi.org/10.12688/f1000research.14116.1
work_keys_str_mv AT wattsjustin recentadvancesintheunderstandingandtreatmentofacutemyeloidleukemia
AT nimerstephen recentadvancesintheunderstandingandtreatmentofacutemyeloidleukemia

Ejemplares similares